Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Molded Devices acquisition of GlobalMed and Schauenburg-Truplast
We advised Molded Devices on the acquisition and the related financing arrangements
Elevance Health $1.8 billion senior notes offering
The investment-grade notes are due 2025, 2032 and 2052
Walgreens $2.25 billion Summit Health-CityMD acquisition financing
We are advising the lender in connection with the facilities
NextGen Healthcare $275 million convertible senior notes offering
The 3.75% convertible notes are due 2027
Johnson & Johnson $16.6 billion acquisition of Abiomed
We are advising J.P. Morgan Securities as financial adviser to Johnson & Johnson
Recursion Pharmaceuticals $150 million private placement
We advised the placement agents on the private placement of common stock
Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Denali Therapeutics $316 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction